Changes in Tardive Dyskinesia Symptoms in Elderly Patients Treated with Ganglioside GM1 or Placebo

Abstract

The unique role of ganglioside GM1 in neuronal plasticity led two centers, New York University and McLean Hospital, to study the effect of GM1 or placebo in patients with tardive dyskinesia. Results from the NYU cohort have already been published. We now present data from the entire cohort, allowing us to evaluate the effects of GM1 in the elderly compared to young adults. Subjects with tardive dyskinesia were randomly assigned to single-blind placebo injections for 1 week, followed by 1 month of double-blind intramuscular placebo or GM1100 mg. The final sample included 29 patients: 12 younger than 55 years of age and 17 older. There was no GM1-versus-placebo difference observed in either-age group, or in the total group. However, whether on placebo or GM1, repeated measures analysis of variance (RANOVA) found a significant difference in response between Abnormal Involuntary Movement Scale scores, taken baseline and week 4, in the elderly compared to young adults. Scores for the young adults show initial improvement then deterioration back to baseline, and those for the elderly show continuing improvement during the 4-week trial. The importance of the placebo effect in the elderly and its meaning for studies of GM1 in tardive dyskinesia are discussed.

Get full access to this article

View all access options for this article.

References

1. Agnati LF , et al. Selective modulation of 3H-spiperone labeled 5-HT receptors by subchronic treatment with ganglioside GM1 in the rat. Acta Physiol Scand 1983; 117:311–314.

2. Agnati LF , et al. Chronic ganglioside treatment counteracts the biochemical signs of dopamine sensitivity induced by chronic haloperidol treatment. Neurosci Lett 1983; 40: 293–297.

3. Caccia MR . Treatment of denervated muscle by gangliosides. Muscle Nerve 1979; 2:382–389.

4. Crepaldi G. Ganglioside treatment in diabetic peripheral neuropathy: a multicenter trial. Acta Diabetol Lat 1983; 20:265–276.

5. Gorio A , et al. Motor nerve sprouting induced by ganglioside treatment. Possible implications for gangliosides on neuronal growth. Brain Res 1980; 197:236–241.

6. Maysinger D , et al. Striatal and cortical acetylcholine release in vivo in rats with unilateral decortication: effects of treatment with monosialoganglioside GM1. Brain Res 1988; 461:355–360.

7. Sabel BA , et al. GM1 ganglioside treatment facilitates behavioral recovery from bilateral brain damage. Science 1984; 225:340–342.

8. Crino PB , et al. Brain gangliosides in dementia of the Alzheimer type. Arch Neurol 1989; 46:398–401.

9. Massarotti M. Ganglioside treatment of alcoholic neuropathies: experimental and clinical aspects. Pharmacol Biochem Behav 1983; 1:51–54.

10.

10. Bassi S , et al. Electromyographic study of diabetic and alcoholic polyneuropathic patients treated with gangliosides. Muscle Nerve 1982; 5:351–356.

11.

11. Baldessarini RJ , Tarsy D. Relationship of the actions of neuroleptic drugs to the pathophysiology of tardive dyskinesia. Int Rev Neurobiol 1979; 21:1–45.

12.

12. Peselow ED , et al. GM1 Ganglioside as a potential treatment in tardive dyskinesia. Psychopharmacol Bull 1989; 25:277–280.

13.

13. Orlando P , et al. The fate of tritium-labeled GM1 ganglioside injected in mice. Pharmacol Res Commun 1979; 11:759–773.

14.

14. Davies DC , et al. Blood-brain barrier in aging and Alzheimer's disease. Neurobiol Aging 1988; 9:46–48.

15.

15. Mooradian AD . Effect of aging on the blood-brain barrier. Neurobiol Aging 1988; 9:31–39.

16.

16. Cohen BM , Sommer BR . Metabolism of thioridazine in the elderly. J Clin Psychopharm 1988; 8:336–339.

17.

17. Bergen JA , et al. The course of tardive dyskinesia in patients on long-term neuroleptics. Br J Psychiatry 1989; 154:523–528.

18.

18. Gardos G , et al. The natural history of tardive dyskinesia. J Clin Psychopharmacol 1988; 8:31S–37S.

19.

19. Frank JD , Frank JB . Persuasion and healing, 3rd Ed. Baltimore: Johns Hopkins University Press, 1991:132–153.